Vaccine Safety Debates Intensify: Social media chatter has highlighted recent studies comparing Pfizer's vaccine profile unfavorably to competitors on issues like clotting risks and cardiovascular effects. Observers note these findings could influence ongoing perceptions of the company's legacy products. Discussions emphasize the need for clearer data transparency from the firm.
Pipeline and Valuation Focus: Analysts on social media point to Pfizer's weight-loss initiatives as a potential growth driver amid broader market rotations away from tech. Some express frustration over the lack of buyer interest despite a high dividend yield and projected free cash flow. Comments suggest the stock's trading multiple reflects skepticism toward fragmented trial outcomes.
Institutional Interest Noted: Recent posts reference substantial holdings by prominent investors in Pfizer shares as a signal of long-term confidence. This comes alongside mentions of the company trading at historically low price levels relative to its cash generation. Overall market sentiment remains watchful ahead of upcoming earnings.
Note: This discussion summary was generated from an AI condensation of post data.
Pfizer Insider Trading Activity
Pfizer insiders have traded $PFE stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PFE stock by insiders over the last 6 months:
- JENNIFER B. DAMICO (SVP & Controller) sold 2,000 shares for an estimated $51,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Pfizer Revenue
Pfizer had revenues of $14.5B in Q1 2026. This is an increase of 5.37% from the same period in the prior year.
You can track PFE financials on Quiver Quantitative's PFE stock page.
You can access data on PFE stock through the Quiver Quantitative API.
Pfizer Congressional Stock Trading
Members of Congress have traded $PFE stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- SENATOR TOMMY TUBERVILLE sold up to $50,000 on 06/08.
- SENATOR ALAN ARMSTRONG sold up to $100,000 on 03/24.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 02/10 and 1 sale worth up to $15,000 on 03/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Pfizer Hedge Fund Activity
We have seen 1,294 institutional investors add shares of Pfizer stock to their portfolio, and 1,351 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FISHER ASSET MANAGEMENT, LLC added 53,012,321 shares (+102.0%) to their portfolio in Q1 2026, for an estimated $1,480,104,002
- GOLDMAN SACHS GROUP INC added 7,058,154 shares (+17.6%) to their portfolio in Q1 2026, for an estimated $197,063,659
- ACADIAN ASSET MANAGEMENT LLC added 6,629,451 shares (+374.1%) to their portfolio in Q1 2026, for an estimated $185,094,271
- BNP PARIBAS FINANCIAL MARKETS removed 6,624,160 shares (-40.1%) from their portfolio in Q1 2026, for an estimated $184,946,547
- AMUNDI removed 6,237,910 shares (-13.3%) from their portfolio in Q1 2026, for an estimated $174,162,447
- ASSENAGON ASSET MANAGEMENT S.A. added 5,829,204 shares (+96.0%) to their portfolio in Q2 2026, for an estimated $140,367,232
- BANK OF NEW YORK MELLON CORP added 5,364,929 shares (+11.1%) to their portfolio in Q1 2026, for an estimated $149,788,817
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Pfizer Government Contracts
We have seen $1,093,194 of award payments to $PFE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PFIZER VACCINES STORAGE AND ROTATION CONTRACT: $410,203
- 4569494415!PROCARDIA XL 30 MG TABLET 100S: $24,723
- 4571408600!PROCARDIA XL 30 MG TABLET 100S: $14,837
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Pfizer Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 12 analysts offer price targets for $PFE in the last 6 months, with a median target of $27.5.
Here are some recent targets:
- Chris Schott from JP Morgan set a target price of $28.0 on 07/08/2026
- Rajesh Kumar from HSBC set a target price of $28.0 on 07/06/2026
- Carter Gould from Cantor Fitzgerald set a target price of $27.0 on 07/06/2026
- Trung Huynh from RBC Capital set a target price of $25.0 on 06/10/2026
- Geoff Meacham from Citigroup set a target price of $27.0 on 04/29/2026
- Jin Zhang from CICC set a target price of $33.0 on 04/16/2026
- Michael Yee from UBS set a target price of $27.0 on 04/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
